Nicollet Investment Management Inc. Acquires 714 Shares of Alkermes plc (NASDAQ:ALKS)

Nicollet Investment Management Inc. increased its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 1.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,845 shares of the company’s stock after purchasing an additional 714 shares during the quarter. Nicollet Investment Management Inc.’s holdings in Alkermes were worth $1,227,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ALKS. Sei Investments Co. boosted its holdings in shares of Alkermes by 10.1% in the 1st quarter. Sei Investments Co. now owns 77,942 shares of the company’s stock valued at $2,110,000 after buying an additional 7,178 shares during the last quarter. ProShare Advisors LLC boosted its position in Alkermes by 8.0% during the first quarter. ProShare Advisors LLC now owns 45,172 shares of the company’s stock worth $1,223,000 after purchasing an additional 3,350 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in shares of Alkermes by 9.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 51,760 shares of the company’s stock valued at $1,459,000 after purchasing an additional 4,410 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Alkermes by 70.6% in the first quarter. Acadian Asset Management LLC now owns 25,781 shares of the company’s stock valued at $697,000 after purchasing an additional 10,671 shares during the period. Finally, Edgestream Partners L.P. boosted its holdings in shares of Alkermes by 206.1% during the 1st quarter. Edgestream Partners L.P. now owns 79,609 shares of the company’s stock worth $2,155,000 after buying an additional 53,600 shares during the period. Institutional investors own 95.21% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. StockNews.com upgraded Alkermes from a “hold” rating to a “buy” rating in a report on Sunday, July 28th. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and upped their price objective for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. Robert W. Baird boosted their target price on shares of Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. decreased their price target on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.42.

Insider Activity

In related news, EVP Craig C. Hopkinson sold 58,996 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.08, for a total value of $1,774,599.68. Following the sale, the executive vice president now owns 83,300 shares of the company’s stock, valued at $2,505,664. The trade was a 41.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.89% of the company’s stock.

Alkermes Stock Down 0.6 %

NASDAQ:ALKS opened at $28.19 on Friday. Alkermes plc has a one year low of $22.06 and a one year high of $32.88. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The company has a market cap of $4.56 billion, a PE ratio of 14.46, a P/E/G ratio of 0.98 and a beta of 0.47. The firm’s 50 day simple moving average is $27.79 and its 200 day simple moving average is $26.22.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.